BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38773978)

  • 1. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing.
    Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F
    Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing.
    Mun D; Kang JY; Kim H; Yun N; Joung B
    J Control Release; 2024 Jun; 370():798-810. PubMed ID: 38754633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical and Functional Characterization of Differential CRISPR-Cas9 Ribonucleoprotein Complexes.
    Camperi J; Moshref M; Dai L; Lee HY
    Anal Chem; 2022 Jan; 94(2):1432-1440. PubMed ID: 34958212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly Efficient Mouse Genome Editing by CRISPR Ribonucleoprotein Electroporation of Zygotes.
    Chen S; Lee B; Lee AY; Modzelewski AJ; He L
    J Biol Chem; 2016 Jul; 291(28):14457-67. PubMed ID: 27151215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome editing via delivery of Cas9 ribonucleoprotein.
    DeWitt MA; Corn JE; Carroll D
    Methods; 2017 May; 121-122():9-15. PubMed ID: 28410976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.
    Miller JB; Zhang S; Kos P; Xiong H; Zhou K; Perelman SS; Zhu H; Siegwart DJ
    Angew Chem Int Ed Engl; 2017 Jan; 56(4):1059-1063. PubMed ID: 27981708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes.
    Jacobi AM; Rettig GR; Turk R; Collingwood MA; Zeiner SA; Quadros RM; Harms DW; Bonthuis PJ; Gregg C; Ohtsuka M; Gurumurthy CB; Behlke MA
    Methods; 2017 May; 121-122():16-28. PubMed ID: 28351759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
    Zhang S; Shen J; Li D; Cheng Y
    Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 mediated high efficiency knockout of the eye color gene Vermillion in Helicoverpa zea (Boddie).
    Perera OP; Little NS; Pierce CA
    PLoS One; 2018; 13(5):e0197567. PubMed ID: 29771955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipofection-mediated genome editing using DNA-free delivery of the Cas9/gRNA ribonucleoprotein into plant cells.
    Liu W; Rudis MR; Cheplick MH; Millwood RJ; Yang JP; Ondzighi-Assoume CA; Montgomery GA; Burris KP; Mazarei M; Chesnut JD; Stewart CN
    Plant Cell Rep; 2020 Feb; 39(2):245-257. PubMed ID: 31728703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Genome Editing Using DNA-Free RNA-Guided Cas9 Ribonucleoprotein for CHO Cell Engineering.
    Shin J; Lee N; Cho S; Cho BK
    Methods Mol Biol; 2018; 1772():151-169. PubMed ID: 29754227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
    Whitley JA; Cai H
    J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scaffold-Based Delivery of CRISPR/Cas9 Ribonucleoproteins for Genome Editing.
    Chooi WH; Chin JS; Chew SY
    Methods Mol Biol; 2021; 2211():183-191. PubMed ID: 33336278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cells.
    Tyumentseva MA; Tyumentsev AI; Akimkin VG
    PLoS One; 2021; 16(11):e0259812. PubMed ID: 34752487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
    Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
    Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-Delivered CRISPR-Cas9 Ribonucleoproteins System for Gene-Editing Screening of Maize Protoplasts.
    Sant'Ana RRA; Caprestano CA; Nodari RO; Agapito-Tenfen SZ
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32887261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a pVEC peptide-based ribonucleoprotein (RNP) delivery system for genome editing using CRISPR/Cas9 in Chlamydomonas reinhardtii.
    Kang S; Jeon S; Kim S; Chang YK; Kim YC
    Sci Rep; 2020 Dec; 10(1):22158. PubMed ID: 33335164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.